What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Gene
- Cancer
Gerhard Rogler mostly deals with Inflammatory bowel disease, Internal medicine, Immunology, Ulcerative colitis and Crohn's disease.
His Inflammatory bowel disease study integrates concerns from other disciplines, such as Microbiome, Irritable bowel syndrome, Incidence, Pathophysiology and Colonoscopy.
His Internal medicine study combines topics in areas such as Gastroenterology and Endocrinology.
His research investigates the connection between Ulcerative colitis and topics such as Primary sclerosing cholangitis that intersect with issues in Erythema nodosum, Pyoderma gangrenosum and Ankylosing spondylitis.
In his study, Evidence-based medicine and Evidence-based practice is strongly linked to Intensive care medicine, which falls under the umbrella field of Crohn's disease.
His work deals with themes such as Young adult and Surgery, which intersect with Disease.
His most cited work include:
- The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis (1222 citations)
- Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. (725 citations)
- Nuclear factor κB is activated in macrophages and epithelial cells of inflamed intestinal mucosa (590 citations)
What are the main themes of his work throughout his whole career to date?
Gerhard Rogler mainly investigates Internal medicine, Inflammatory bowel disease, Crohn's disease, Immunology and Ulcerative colitis.
His work carried out in the field of Internal medicine brings together such families of science as Gastroenterology and Endocrinology.
Gerhard Rogler interconnects Prospective cohort study, Azathioprine, Colitis and Intensive care medicine in the investigation of issues within Inflammatory bowel disease.
His Crohn's disease research is multidisciplinary, incorporating elements of Antibody and Surgery.
His study involves Inflammation, Immune system, Tumor necrosis factor alpha, NOD2 and Pathogenesis, a branch of Immunology.
His study explores the link between Ulcerative colitis and topics such as Infliximab that cross with problems in Adalimumab.
He most often published in these fields:
- Internal medicine (39.40%)
- Inflammatory bowel disease (32.74%)
- Crohn's disease (24.95%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (39.40%)
- Inflammatory bowel disease (32.74%)
- Crohn's disease (24.95%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Internal medicine, Inflammatory bowel disease, Crohn's disease, Ulcerative colitis and Gastroenterology.
His study in the field of Cohort study, Cohort and Tumor necrosis factor alpha also crosses realms of In patient.
His study in Inflammatory bowel disease is interdisciplinary in nature, drawing from both Microbiome, Inflammation, Colitis, Immunology and Intensive care medicine.
His study with Crohn's disease involves better knowledge in Disease.
His Ulcerative colitis research is multidisciplinary, incorporating perspectives in Adverse effect and Tofacitinib.
His Gastroenterology research incorporates themes from Ingestion, Calprotectin and Gluten free.
Between 2016 and 2021, his most popular works were:
- 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2: Surgical Management and Special Situations. (329 citations)
- Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis. (151 citations)
- Vagus Nerve as Modulator of the Brain-Gut Axis in Psychiatric and Inflammatory Disorders. (142 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Gene
- Cancer
Inflammatory bowel disease, Internal medicine, Crohn's disease, Ulcerative colitis and Gastroenterology are his primary areas of study.
The study incorporates disciplines such as Tumor necrosis factor alpha, Inflammation, Colitis, Immunology and Cohort study in addition to Inflammatory bowel disease.
His work in the fields of Odds ratio, Cohort, Proportional hazards model and Adverse effect overlaps with other areas such as In patient.
Gerhard Rogler has researched Crohn's disease in several fields, including Clinical trial, Surgery and Intensive care medicine.
His Ulcerative colitis study integrates concerns from other disciplines, such as Microbiome, Bioinformatics, Gut flora, Tofacitinib and Drug.
His study looks at the relationship between Gastroenterology and topics such as Abrilumab, which overlap with Moderate to severe, Multiple dose and Double blind.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
